Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 350
Filtrar
1.
Arch Dermatol Res ; 316(8): 603, 2024 Sep 06.
Artigo em Inglês | MEDLINE | ID: mdl-39240378

RESUMO

This study systematically evaluated and ranked the efficacy of first- and second-line antibiotics antibiotic options for the clinical management of cellulitis and erysipelas through a network meta-analysis approach. From inception to July 04, 2024, a search for relevant randomized clinical trials (RCTs) was carried out using several databases. Antibiotics including azithromycin, cefaclor, cephalexin, cloxacillin, erythromycin, cephalexin plus trimethoprim-sulfamethoxazole, cephalexin plus placebo, flucloxacillin, clindamycin, ceftriaxone, penicillin, roxithromycin, and pristinamycin were assessed regarding cure rate, the eradication of baseline pathogens, diarrhea or vomiting, and rash. In total, 10 RCTs with 1,936 cellulitis or erysipelas patients were eligible for inclusion. There were no significant differences in the cure rates for cellulitis among the antibiotics analysed, with cefaclor demonstrating the most favorable profile for curative outcomes. In terms of side effects, ceftriaxone was identified as the least likely to induce diarrhea or vomiting. For erysipelas, pristinamycin showed the most promising results in achieving cure rates. Although a comparison of the three antibiotics revealed no significant differences in rash as a side effect in erysipelas, pristinamycin was observed to carry the highest risk for rash. Our findings indicate no significant differences in cure rates among antibiotics for cellulitis. However, ceftriaxone had the fewest gastrointestinal side effects. Pristinamycin showed the highest cure rates for erysipelas but with a higher risk of rash. Future research should focus on optimizing antibiotic selection for cellulitis and erysipelas.


Assuntos
Antibacterianos , Celulite (Flegmão) , Erisipela , Metanálise em Rede , Humanos , Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Celulite (Flegmão)/tratamento farmacológico , Erisipela/tratamento farmacológico , Pristinamicina/administração & dosagem , Pristinamicina/efeitos adversos , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento
3.
Eur J Public Health ; 34(5): 860-865, 2024 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-38996407

RESUMO

Hospitals at home are increasingly offering outpatient parenteral antimicrobial therapy (OPAT) in an attempt to reduce costly inpatient care, but these settings favour broad-spectrum antibiotics that require less frequent dosing than penicillin. Benzyl penicillin could be delivered via continuous infusion pumps (eCIPs), but studies on their safety and efficacy in OPAT are scarce, and it remains unclear how much the availability of eCIPs increases penicillin use in real-life settings. We examined 462 electronic healthcare records of erysipelas patients treated between January 2018 and January 2022 in a large Finnish OPAT clinic. Average marginal effects from logistic models were estimated to assess how the introduction of eCIPs in December 2020 affected penicillin use and to compare clinical outcomes between patients with and without eCIPs. Introduction of eCIPs increased the predicted probability of penicillin treatment by 36.0 percentage points (95% confidence interval 25.5-46.5). During eCIP implementation, patients who received an eCIP had 73.1 (58.0-88.2) percentage points higher probability than patients without an eCIP to receive penicillin treatment. They also had about 20 percentage points higher probability to be cured at the time of discharge and 3 months after it. Patient and nurse satisfaction regarding eCIPs was very high. Benzyl penicillin eCIP treatment is effective and safe, and substantially increases the use of penicillin instead of broad-spectrum antibiotics. To reduce the risk of antimicrobial resistance, eCIPs could increasingly be promoted for use in OPAT clinics, and there should be adequate education and support in their implementation.


Assuntos
Antibacterianos , Erisipela , Bombas de Infusão , Penicilinas , Humanos , Feminino , Masculino , Pessoa de Meia-Idade , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Finlândia , Idoso , Penicilinas/administração & dosagem , Penicilinas/uso terapêutico , Erisipela/tratamento farmacológico , Adulto , Guias de Prática Clínica como Assunto , Idoso de 80 Anos ou mais
4.
Przegl Epidemiol ; 78(1): 27-43, 2024 Jun 07.
Artigo em Inglês, Polonês | MEDLINE | ID: mdl-38904310

RESUMO

Infectious skin diseases constitute a significant public health problem. Despite the systematic development of many modern diagnostic and therapeutic tools, they still pose a serious challenge for clinicians. Due to their prevalence and mild course in most cases, they are often marginalized, which can delay their diagnosis and treatment initiation. Such an approach in more clinically advanced cases can have serious consequences, sometimes leading to tragic outcomes. This work presents a series of four cases of common infectious skin diseases with an unusually atypical clinical picture: the history of a 49-year-old female patient with recurrent erysipelas of the right lower leg co-occurring with a SARS-CoV-2 infection, a 75-year-old male patient with a generalized form of herpes zoster, a 38-year-old female patient with a complicated severe course of head lice, and a 34-year-old male patient with a severe form of post-steroid mycosis. In each of these cases, difficulties in making the correct diagnosis were highlighted, even though they represent some of the most common bacterial, viral, parasitic, and fungal dermatoses. The paper discusses the risk factors for these diseases, the pathophysiology of their atypical course, the effects and challenges in the therapeutic approach conducted. Infectious skin dermatoses require aggressive treatment and should never be underestimated.


Assuntos
COVID-19 , Dermatopatias Infecciosas , Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Adulto , COVID-19/diagnóstico , Dermatopatias Infecciosas/diagnóstico , Dermatopatias Infecciosas/terapia , Dermatopatias Infecciosas/tratamento farmacológico , Herpes Zoster/diagnóstico , Herpes Zoster/tratamento farmacológico , SARS-CoV-2 , Erisipela/diagnóstico , Erisipela/tratamento farmacológico
5.
FP Essent ; 541: 14-19, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38896826

RESUMO

Bacterial skin infections represent a significant health care burden. Cellulitis and erysipelas are rapidly spreading, painful, superficial skin infections, usually caused by streptococci or Staphylococcus aureus. Folliculitis is an infection of hair follicles mostly caused by S aureus. Simple folliculitis typically is self-limited. Topical benzoyl peroxide is a first-line nonantibiotic treatment. Mupirocin and clindamycin are topical antibiotic options. For treatment-resistant cases, oral cephalexin or dicloxacillin is an appropriate option. Impetigo is a common, self-limited infection in children. Bullous impetigo is caused by S aureus, and nonbullous impetigo is caused by beta-hemolytic streptococci, S aureus, or both. In most cases, topical mupirocin or retapamulin (Altabax) is effective. Oral antibiotics should be considered for household outbreaks or patients with multiple lesions. Abscesses are red, painful collections of purulence in the dermis and deeper tissues caused by S aureus or polymicrobial infections. Furuncles are abscesses of a hair follicle, whereas carbuncles involve several hair follicles. In recurrent cases of these lesions, culture of the exudate is recommended. Abscess, furuncle, and carbuncle management consists of incision and drainage. Oral antibiotics are not necessary in most cases but should be prescribed for patients with severe immunocompromise or systemic signs of infection. In bacterial skin infections, methicillin-resistant S aureus coverage should be considered for patients with infections that have not improved with treatment.


Assuntos
Antibacterianos , Celulite (Flegmão) , Impetigo , Dermatopatias Bacterianas , Humanos , Criança , Antibacterianos/uso terapêutico , Adolescente , Impetigo/diagnóstico , Impetigo/tratamento farmacológico , Dermatopatias Bacterianas/diagnóstico , Dermatopatias Bacterianas/tratamento farmacológico , Dermatopatias Bacterianas/microbiologia , Dermatopatias Bacterianas/terapia , Celulite (Flegmão)/diagnóstico , Celulite (Flegmão)/tratamento farmacológico , Celulite (Flegmão)/microbiologia , Celulite (Flegmão)/terapia , Foliculite/diagnóstico , Foliculite/tratamento farmacológico , Foliculite/microbiologia , Erisipela/diagnóstico , Erisipela/tratamento farmacológico , Abscesso/diagnóstico , Abscesso/terapia , Abscesso/microbiologia , Furunculose/diagnóstico , Furunculose/tratamento farmacológico , Furunculose/terapia , Furunculose/microbiologia , Carbúnculo/diagnóstico , Carbúnculo/terapia
6.
Transplant Proc ; 56(4): 976-980, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38448250

RESUMO

Erysipelas/cellulitis are severe skin infections that are especially dangerous for immunocompromised patients. The most common cause of these diseases is streptococcal infection, but sometimes they may be caused by other Gram-positive or negative bacteria or other factors. Proper diagnosis and treatment should be implemented accurately to prevent dangerous complications. We present a case of severe bullous erysipelas caused by Escherichia coli and discuss the diagnosis, differential diagnosis, and treatment of cellulitis in kidney transplant patients.


Assuntos
Celulite (Flegmão) , Erisipela , Transplante de Rim , Humanos , Transplante de Rim/efeitos adversos , Erisipela/tratamento farmacológico , Celulite (Flegmão)/microbiologia , Celulite (Flegmão)/tratamento farmacológico , Infecções por Escherichia coli/microbiologia , Infecções por Escherichia coli/tratamento farmacológico , Masculino , Escherichia coli/isolamento & purificação , Antibacterianos/uso terapêutico , Pessoa de Meia-Idade , Hospedeiro Imunocomprometido
7.
Infect Dis Now ; 54(3): 104887, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38492802

RESUMO

BACKGROUND: New skin and soft tissue infections (SSTI) guidelines were published in 2019 in France, changing the recommended duration for antibiotic treatment. The objective of the present study was to assess the impact of the publication of the 2019 French guidelines on SSTIs on the duration of antibiotic prescription for erysipelas. METHODS: In a before-after study (a year before and a year after April 1st, 2019), we included all adult patients diagnosed with erysipelas in Reims University Hospital medical wards and the emergency department. We retrospectively retrieved antibiotic prescription duration in the patients' medical files. RESULTS: Among 50 patients in the "before" and 39 in the "after" group, the mean duration of antibiotic prescription was significantly shorter in the "after" group (9.4 ± 2.8 vs. 12.4 ± 3.8 days, p = 0.0001). CONCLUSIONS: A 25% decrease in the duration of antibiotic prescription for erysipelas was observed following the implementation of these guidelines, providing useful information for an antibiotic stewardship policy.


Assuntos
Erisipela , Infecções dos Tecidos Moles , Adulto , Humanos , Antibacterianos/uso terapêutico , Erisipela/tratamento farmacológico , Infecções dos Tecidos Moles/tratamento farmacológico , Infecções dos Tecidos Moles/diagnóstico , Estudos Retrospectivos , Estudos Controlados Antes e Depois , Prescrições , Hospitais Universitários
10.
Hautarzt ; 73(3): 223-233, 2022 Mar.
Artigo em Alemão | MEDLINE | ID: mdl-35084520

RESUMO

Acute skin and soft tissue infections are among the most frequent infections in medicine. There is a broad spectrum including simple local infections as well as severe and life-threatening diseases. Along with Staphylococcus aureus, group A Streptococci are mainly responsible for these illnesses. The therapeutic approach ranges from antiseptic local treatments to administering systemic antibiotics or emergency surgery. Treating physicians often face challenges when presented with soft tissue infections due to a great discrepancy between the first impression of the disease compared to a possibly quick progression as well as the wide range of sometimes confusing historic terms and definitions being used in the English and German language, for instance pyoderma, erysipelas or phlegmon. A recently more popular collective term emphasized by clinical trials is "acute bacterial skin and skin structure infections" (ABSSSI).


Assuntos
Erisipela , Dermatopatias Bacterianas , Dermatopatias Infecciosas , Infecções dos Tecidos Moles , Infecções Estafilocócicas , Antibacterianos/uso terapêutico , Celulite (Flegmão)/tratamento farmacológico , Celulite (Flegmão)/microbiologia , Erisipela/diagnóstico , Erisipela/tratamento farmacológico , Humanos , Dermatopatias Bacterianas/diagnóstico , Dermatopatias Bacterianas/tratamento farmacológico , Dermatopatias Infecciosas/diagnóstico , Dermatopatias Infecciosas/tratamento farmacológico , Infecções dos Tecidos Moles/diagnóstico , Infecções dos Tecidos Moles/tratamento farmacológico
11.
Ann Dermatol Venereol ; 149(2): 119-122, 2022 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-34742579

RESUMO

BACKGROUND: Erysipelas is a common infection of the superficial layer of skin. The main causative agent is group A ß-hemolytic streptococci. One of the most challenging aspects of this disease is its high rate of recurrence. OBJECTIVES: To identify risk factors for recurrence of erysipelas of the leg. PATIENTS AND METHODS: We included in a cross-sectional study all patients hospitalized for erysipelas of the leg seen at the dermatology department of the Ibn Rochd University Hospital in Casablanca, Morocco, from January 2015 to April 2020. Patients were divided into two groups: those with a single episode (SE) and those with recurrent erysipelas (RE). These two groups were compared for clinical and laboratory characteristics, with particular focus on systemic and local risk factors. RESULTS: The study included 270 patients, of whom 132 had SE and 138 had RE. Age, gender, hospital stay as well as laboratory findings did not differ significantly between the two groups. In multivariable analysis, cutaneous disruption [adjusted odds ratio (aOR)=1.9; 95% confidence interval (95% CI): 1.0-3.71], lymphedema [aOR=19.6; 95% CI: 8.0-57.2], and obesity [aOR=2.3; 95% CI: 1.1-5.2] were significantly associated with RE. Venous insufficiency and diabetes were not found to be associated with risk of recurrence. CONCLUSION: Our results suggest that erysipelas is a potentially chronic disease and patients with identified local risk factors or obesity should be considered as exposed to recurrence and considered as targets for antibiotic prophylaxis and other preventive methods.


Assuntos
Erisipela , Estudos Transversais , Erisipela/tratamento farmacológico , Humanos , Perna (Membro) , Obesidade/complicações , Obesidade/epidemiologia , Recidiva , Fatores de Risco
12.
Adv Clin Exp Med ; 30(9): 981-985, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-34410045

RESUMO

BACKGROUND: Erysipelas is an acute skin infection caused by group A and G streptococci. This infection is associated with many comorbidities and often requires hospitalization. OBJECTIVES: The aim of this study was to identify the factors related to the length of hospitalization in patients with erysipelas. MATERIAL AND METHODS: This retrospective study included 153 admissions of 135 patients (63 women and 72 men) hospitalized due to erysipelas from January 2010 to December 2019. Clinical symptoms, test results, comorbidities, and antibiotic treatments were taken into consideration as factors affecting the length of hospital stay. RESULTS: The median length of hospitalization was 10 days (interquartile range (IQR) = 7-14). Women spent less time in the ward, but the difference was not significant. Features such as tinea pedis (15.5 days, IQR = 13.5-20; p = 0.002), anemia (11 days, IQR = 9-15; p = 0.02), chills (12 days, IQR = 9-15; p = 0.03), elevated serum C-reactive protein (CRP) level over 100 mg/L (11 days, IQR = 8-17; p = 0.02), and leukocytosis (11 days, IQR = 8-15, p = 0.005) were identified as prolonged hospitalization factors. Moreover, patients with erysipelas localized to the legs (p = 0.01) and with a gangrenous variant of erysipelas (p = 0.03) were hospitalized longer. The first-choice antibiotic was not significant in terms of prolonged hospitalization. Patients treated with clindamycin during hospitalization, regardless of whether it was a first-line or subsequent antibiotic, stayed in the ward significantly longer (p = 0.005). CONCLUSION: Patients suffering from erysipelas with the features identified above, have a higher risk of a prolonged stay in the hospital. Significantly increased inflammatory factors, anemia and tinea pedis contributed to prolonged hospitalization.


Assuntos
Erisipela , Antibacterianos/uso terapêutico , Erisipela/diagnóstico , Erisipela/tratamento farmacológico , Erisipela/epidemiologia , Feminino , Hospitalização , Humanos , Tempo de Internação , Masculino , Polônia/epidemiologia , Estudos Retrospectivos
13.
J Med Case Rep ; 15(1): 365, 2021 Jul 13.
Artigo em Inglês | MEDLINE | ID: mdl-34253232

RESUMO

BACKGROUND: Bordetella trematum is unknown to most clinicians and microbiologists. However, this Gram-negative opportunistic bacterium can be responsible for ulcer superinfection but also bacteremia and sometimes death by septic shock. CASE REPORT: We report the case of erysipelas due to B. trematum with bacteremia in an immunocompromised 88-year-old Caucasian patient. CONCLUSION: In immunocompromised patients, unusual microbial agents such as B. trematum can be responsible for cutaneous and systemic infections, requiring specific antibiotic therapy. Therefore, clinicians should be aware of the need for specific bacterial identification such as matrix-assisted laser desorption ionization time-of-flight mass spectrometry and 16S ribosomal RNA sequencing in the context of atypical evolution of erysipelas in such patients.


Assuntos
Bacteriemia , Bordetella , Erisipela , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Braço , Bacteriemia/tratamento farmacológico , Bordetella/genética , Erisipela/diagnóstico , Erisipela/tratamento farmacológico , Humanos , RNA Ribossômico 16S
14.
Med Clin North Am ; 105(4): 783-797, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-34059250

RESUMO

This evidence-based review highlights cutaneous infections of bacterial, viral, and fungal origin that are frequently encountered by clinicians in all fields of practice. With a focus on treatment options and management, the scope of this article is to serve as a reference for physicians, regardless of field of specialty, as they encounter these pathogens in clinical practice.


Assuntos
Infecções Bacterianas/patologia , Infecções por Herpesviridae/patologia , Micoses/patologia , Dermatopatias Infecciosas/tratamento farmacológico , Dermatopatias Infecciosas/patologia , Adolescente , Adulto , Infecções Bacterianas/complicações , Infecções Bacterianas/microbiologia , Criança , Pré-Escolar , Ectima/diagnóstico , Ectima/tratamento farmacológico , Erisipela/diagnóstico , Erisipela/tratamento farmacológico , Eritema Multiforme/diagnóstico , Eritema Multiforme/tratamento farmacológico , Fasciite Necrosante/diagnóstico , Fasciite Necrosante/tratamento farmacológico , Foliculite/diagnóstico , Foliculite/tratamento farmacológico , Herpes Genital/diagnóstico , Herpes Genital/tratamento farmacológico , Herpes Labial/diagnóstico , Herpes Labial/tratamento farmacológico , Infecções por Herpesviridae/complicações , Infecções por Herpesviridae/virologia , Humanos , Impetigo/diagnóstico , Impetigo/tratamento farmacológico , Erupção Variceliforme de Kaposi/diagnóstico , Erupção Variceliforme de Kaposi/tratamento farmacológico , Pessoa de Meia-Idade , Micoses/complicações , Micoses/microbiologia , Onicomicose/diagnóstico , Onicomicose/tratamento farmacológico , Padrões de Prática Médica/estatística & dados numéricos , Dermatopatias Infecciosas/microbiologia , Dermatopatias Infecciosas/virologia , Tinha do Couro Cabeludo/diagnóstico , Tinha do Couro Cabeludo/tratamento farmacológico , Adulto Jovem
15.
BMC Infect Dis ; 21(1): 26, 2021 Jan 07.
Artigo em Inglês | MEDLINE | ID: mdl-33413190

RESUMO

BACKGROUND: Erysipelas is a common skin infection that is prone to recur. Recurrent erysipelas has a severe effect on the quality of life of patients. The present study aimed to investigate the risk factors of recurrent erysipelas in adult Chinese patients. METHODS: A total of 428 Chinese patients with erysipelas who met the inclusion criteria were studied. The patients were divided into the nonrecurrent erysipelas group and the recurrent erysipelas group. Clinical data were collected on the first episode and relapse of erysipelas. The patients were followed up every 3 months. Statistical analysis was performed to analyze and determine the risk factors of erysipelas relapse. RESULTS: Univariate analysis was performed to analyze the data, including surgery, types of antibiotics administered in the first episode, obesity, diabetes mellitus, venous insufficiency, lymphedema, and malignancy. The differences between the groups were statistically significant (p < 0.05). The Cox proportional hazards regression model analysis showed that the final risk factors included surgery, obesity, diabetes mellitus, venous insufficiency, and lymphedema. CONCLUSIONS: Surgery, obesity, diabetes mellitus, venous insufficiency, and lymphedema are considered as risk factors for recurrent erysipelas.


Assuntos
Erisipela/tratamento farmacológico , Erisipela/etiologia , Adulto , Idoso , Antibacterianos/uso terapêutico , Povo Asiático , Diabetes Mellitus/etiologia , Feminino , Humanos , Linfedema/etiologia , Masculino , Pessoa de Meia-Idade , Obesidade/etiologia , Estudos Prospectivos , Recidiva , Fatores de Risco , Insuficiência Venosa/etiologia
17.
Hautarzt ; 72(1): 34-41, 2021 Jan.
Artigo em Alemão | MEDLINE | ID: mdl-32930854

RESUMO

In many medical expert recommendations and guidelines, the use of compression therapy for acute erysipelas is designated as a contraindication. Due to the sometimes massive oedema, compression therapy is nevertheless used in some clinics. This led to the question whether compression therapy for erysipelas of the lower leg actually leads to complications due to the acute infection and thus represents a contraindication. For the period 01 January 2018 to 30 June 2019, the records of 56 inpatients with acute erysipelas of the lower leg who received compression therapy in addition to systemic antibiotic therapy were retrospectively evaluated. The duration of inpatient treatment, the infection parameters determined as part of the ward routine and any complications that occurred were evaluated. While treated as inpatients the blood parameters for infection clearly dropped. Compression therapy was started on admission day in 92.9% of patients and continued until discharge. None of the patients showed an increase in fever or clinical signs of sepsis during the hospital stay. In this retrospective analysis it could be shown for the first time that compression therapy does not cause a clinical worsening or trigger a septic clinical picture in patients with acute erysipelas. Therefore, the authors consider the declaration of acute erysipelas as contraindication for compression therapy as not justified.


Assuntos
Erisipela , Antibacterianos/uso terapêutico , Celulite (Flegmão)/tratamento farmacológico , Celulite (Flegmão)/terapia , Erisipela/tratamento farmacológico , Erisipela/terapia , Humanos , Perna (Membro) , Estudos Retrospectivos
19.
Clin Exp Rheumatol ; 38 Suppl 127(5): 101-104, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33124556

RESUMO

OBJECTIVES: Erysipelas-like erythema (ELE) is a well-known pathognomonic skin lesion associated with familial Mediterranean fever (FMF). The aim of this study was to describe the clinical and demographic features and phenotypic differences between paediatric FMF patients with and without ELE. METHODS: We retrospectively collected the medical charts of paediatric patients who had been diagnosed with FMF and followed by the Paediatric Rheumatology Department of Gazi University, Turkey, from 2006 to 2016. RESULTS: Among 782 FMF patients, 59 (33 males and 26 females; median age, 11.1±5.1) were found to have ELE. More patients had arthritis in the ELE group than in the other group (p=0.011). Arthritis occurred in the ankle (77.4%), knee (19.3%) and hip (3.2%) joints. The coexistence of arthritis and ELE was seen in 12 (20.3%) patients. All ELE plaques were located on the lower legs and dorsum of the feet. Eleven patients (18.6%) presented with ELE as the initial symptom and were diagnosed with FMF, and 48 (81.4%) patients experienced ELE attacks while receiving colchicine therapy. The median dose of colchicine at last visit, PRAS activity score and M694V homozygous mutation status were significantly higher in the ELE group than in the other group (p=0.041, p=0.001 and p=0.023, respectively). CONCLUSIONS: ELE is an uncommon but important feature of FMF. In patients with ELE, arthritis is more frequently encountered, and M694V homozygous mutation is more frequently found. FMF patients with ELE have more severe disease activity, and they use higher doses of colchicine in relation to this severe disease course.


Assuntos
Erisipela , Febre Familiar do Mediterrâneo , Adolescente , Criança , Erisipela/diagnóstico , Erisipela/tratamento farmacológico , Erisipela/epidemiologia , Eritema/diagnóstico , Eritema/tratamento farmacológico , Eritema/epidemiologia , Febre Familiar do Mediterrâneo/complicações , Febre Familiar do Mediterrâneo/diagnóstico , Febre Familiar do Mediterrâneo/tratamento farmacológico , Feminino , Humanos , Masculino , Mutação , Pirina/genética , Estudos Retrospectivos , Turquia/epidemiologia
20.
J Dtsch Dermatol Ges ; 18(12): 1417-1424, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33035396

RESUMO

BACKGROUND AND OBJECTIVES: Erysipelas, caused by beta-hemolytic streptococci, and limited cellulitis, frequently caused by Staphylococcus aureus or other bacteria, are skin and soft tissue infections characterized by typical clinical signs. However, despite the therapeutical relevance they are often not differentiated (e.g in clinical trials). Erysipelas are efficiently treated with penicillin, while limited cellulitis is treated with more wide-spectrum antibiotics. This study investigates whether parameters such as CRP, blood counts or novel parameters like immature granulocytes could serve as biomarkers to distinguish between these entities. PATIENTS AND METHODS: For this retrospective analysis 163 patients were included. We compared laboratory markers in patients with erysipelas (n = 68) to those with limited cellulitis (n = 41) of the leg. Both erysipelas and limited cellulitis were defined clinically, with an additional aspect for erysipelas being a prompt response to penicillin. RESULTS: Erysipelas were characterized by higher levels of inflammation. CRP and leukocyte counts are the best parameters to discriminate between both infections. A CRP value ≥ 3.27 mg/dl indicated the diagnosis of erysipelas with 75 % sensitivity and 73.2 % specificity. CONCLUSIONS: Our results support the thesis that erysipelas and limited cellulitis are distinct infections as defined in the German guidelines and that an assessment of CRP and leukocytes is useful for differential diagnosis.


Assuntos
Erisipela , Infecções dos Tecidos Moles , Antibacterianos/uso terapêutico , Celulite (Flegmão)/diagnóstico , Celulite (Flegmão)/tratamento farmacológico , Erisipela/diagnóstico , Erisipela/tratamento farmacológico , Humanos , Laboratórios , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA